Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranolazine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ranolazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2017
Lead Product(s) : Ranolazine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Esomeprazole is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Helicobacter Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 09, 2016
Lead Product(s) : Esomeprazole Magnesium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF
Details : Colchicine is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atrial Fibrillation.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 21, 2015
Lead Product(s) : Colchicine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Efzofitimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Efzofitimod is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Asthma.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 02, 2011
Lead Product(s) : Efzofitimod
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
